Silke Kapp‐Schwoerer

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Sibylle Cocciardi, Anna Dolnik, Silke Kapp‐Schwoerer et al. · Nature Communications · 2019 · 124 citations · Full text

Medicine, Genetics, Oncology +17

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial

Silke Kapp‐Schwoerer, Daniela Weber, Andrea Corbacioglu et al. · Blood · 2020 · 119 citations · Full text

Medicine, Oncology, Pharmacology +10

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu et al. · Blood · 2019 · 118 citations · Full text

Medicine, Hematology, Oncology +16

Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk, Peter Paschka, Julia Krzykalla et al. · Journal of Clinical Oncology · 2019 · 112 citations · Full text

Medicine, Hematology, Oncology +15

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

Verena I. Gaidzik, Daniela Weber, Peter Paschka et al. · Leukemia · 2017 · 66 citations

Medicine, Genetics, Molecular Genetics +12